Addiction to c-MYC in multiple myeloma
作者： Toril Holien , Thea Kristin Våtsveen , Hanne Hella , Anders Waage , Anders Sundan
DOI: 10.1182/BLOOD-2011-08-371567
关键词:
摘要: In multiple myeloma, c-MYC is activated and contributes to the malignant phenotype. Targeting MYC by short hairpin RNA induced cell death in myeloma lines; however, lines are generated from samples taken advanced stages of disease may not reflect patient cells adequately. this study, we used selective small molecule inhibitor MYC-MAX heterodimerization, 10058-F4, on as well primary cells, show that inhibition activity efficiently induces death. Moreover, cocultures with bone marrow stromal patients, still apoptosis. Our results provide further evidence addicted a promising therapeutic target myeloma.
ashpublications.org
bloodjournal.org参考文章(17)
Thea Kristin Våtsveen, Erming Tian, Stine H. Kresse, Leonardo A. Meza-Zepeda, Ana Gabrea, Oleg Glebov, Hong Yan Dai, Anders Sundan, W. Michael Kuehl, Magne Børset, OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leukemia Research. ,vol. 33, pp. 1670- 1677 ,(2009) , 10.1016/J.LEUKRES.2009.03.001
Arthur L. Shaffer, N. C. Tolga Emre, Laurence Lamy, Vu N. Ngo, George Wright, Wenming Xiao, John Powell, Sandeep Dave, Xin Yu, Hong Zhao, Yuxin Zeng, Bangzheng Chen, Joshua Epstein, Louis M. Staudt, IRF4 addiction in multiple myeloma. Nature. ,vol. 454, pp. 226- 231 ,(2008) , 10.1038/NATURE07064
Jin-Jian Lu, Ling-Hua Meng, Uma T. Shankavaram, Cai-Hua Zhu, Lin-Jiang Tong, Guang Chen, Li-Ping Lin, John N. Weinstein, Jian Ding, Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochemical Pharmacology. ,vol. 80, pp. 22- 30 ,(2010) , 10.1016/J.BCP.2010.02.016
H. Jernberg-Wiklund, M. Pettersson, L-G. Larsson, R. Anton, K. Nilsson, Expression of myc-family genes in established human multiple myeloma cell lines: L-myc but not c-myc gene expression in the U-266 myeloma cell line. International Journal of Cancer. ,vol. 51, pp. 116- 123 ,(1992) , 10.1002/IJC.2910510121
Ilsa Gomez-Curet, R. Serene Perkins, Ryan Bennett, Katherine L. Feidler, Stephen P. Dunn, Leslie J. Krueger, c-Myc inhibition negatively impacts lymphoma growth. Journal of Pediatric Surgery. ,vol. 41, pp. 207- 211 ,(2006) , 10.1016/J.JPEDSURG.2005.10.025
WJ Chng, GF Huang, TH Chung, SB Ng, N Gonzalez-Paz, T Troska-Price, G Mulligan, M Chesi, PL Bergsagel, R Fonseca, None, Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma Leukemia. ,vol. 25, pp. 1026- 1035 ,(2011) , 10.1038/LEU.2011.53
Manik Chatterjee, Dirk Hönemann, Suzanne Lentzsch, Kurt Bommert, Christine Sers, Pia Herrmann, Stephan Mathas, Bernd Dörken, Ralf C. Bargou, In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway Blood. ,vol. 100, pp. 3311- 3318 ,(2002) , 10.1182/BLOOD-2002-01-0102
Chadd E Nesbit, Jean M Tersak, Edward V Prochownik, MYC oncogenes and human neoplastic disease Oncogene. ,vol. 18, pp. 3004- 3016 ,(1999) , 10.1038/SJ.ONC.1202746
Xiaoying Yin, Christine Giap, John S Lazo, Edward V Prochownik, Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. ,vol. 22, pp. 6151- 6159 ,(2003) , 10.1038/SJ.ONC.1206641
Jianxia Guo, Robert A. Parise, Erin Joseph, Merrill J. Egorin, John S. Lazo, Edward V. Prochownik, Julie L. Eiseman, Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemotherapy and Pharmacology. ,vol. 63, pp. 615- 625 ,(2009) , 10.1007/S00280-008-0774-Y